Osteoporosis therapies--future leads and current clinical trials. 13-14 December 1999, London, UK.
This IBC conference focused on research areas most likely to generate novel leads for future osteoporosis therapies. There was particular emphasis placed on inhibitors of bone resorption, including progress in the development of existing compounds, such as raloxifene (Evista; Eli Lilly & Co) and the nitrogen-containing bisphosphonates, as well as insights into novel agents, such as the integrin receptors. It was also generally accepted that the next generation of osteoporosis therapies would target osteoblasts with a view to stimulating bone formation. Potential for developing such novel therapies using genomic approaches was also presented.
Bennett
S
S
Oxagen Ltd, 91 Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK. s.bennett@oxagen.co.uk